Skip to Content

Arava (leflunomide) Disease Interactions

There are 7 disease interactions with Arava (leflunomide):

Major

Leflunomide (Includes Arava) ↔ immunosuppression

Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Immunodeficiency, Bone Marrow Depression/Low Blood Counts

Pancytopenia, agranulocytosis and thrombocytopenia have been reported in patients receiving leflunomide. Leflunomide is an immunomodulatory agent with antiproliferative activity. The use of leflunomide is not recommended in patients with severe immunodeficiency, bone marrow dysplasia, or severe, uncontrolled infections because of the theoretical potential for immunosuppression. Care should be taken when using this agent in patients with a prior history of a significant hematologic abnormality. It is recommended to monitor blood levels at baseline and regularly during the course of therapy. If evidence of bone marrow suppression occurs, stop treatment and institute appropriate measures according to clinical guidelines.

References

  1. "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Major

Leflunomide (Includes Arava) ↔ liver disease

Severe Potential Hazard, High plausibility. Applies to: Liver Disease

Severe liver injury, including fatal liver failure, has been reported in patients treated with leflunomide. Leflunomide is contraindicated in patients with severe hepatic impairment. Leflunomide has been commonly associated with elevations in liver enzymes, primarily ALT and AST. Marked elevations occurred infrequently and reversed with dose reduction or discontinuation of treatment. Leflunomide also must be metabolized by the liver into the active compound which is responsible for the in vivo activity. Therapy with leflunomide is not recommended in patients with preexisting liver disease. Dosage adjustment or discontinuation is recommended for patients experiencing liver enzyme elevations while on leflunomide.

References

  1. "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Major

Leflunomide (Includes Arava) ↔ peripheral neuropathy

Severe Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus, Peripheral Neuropathy

Peripheral neuropathy has been reported during leflunomide therapy. Patients older than 60 years, patients taking concomitant neurotoxic medications, and diabetics may be at an increased risk for peripheral neuropathy. Therapy with leflunomide should be administered cautiously in these patients. Patients should be monitored for symptoms of neuropathy and if confirmed, consider discontinuing therapy and taking measures according to clinical practice.

Major

Leflunomide (Includes Arava) ↔ pulmonary toxicity

Severe Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

The use of leflunomide has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), and worsening of preexisting interstitial lung disease have been reported. Caution is recommended when using this agent in patients with a history of ILD or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as cough and dyspnea, with or without associated fever. If ILD is confirmed, consider discontinuing therapy and institute appropriate measures according to clinical guidelines.

Major

Leflunomide (Includes Arava) ↔ renal dysfunction

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction

The active metabolite of leflunomide is elevated in the plasma of patients with renal impairment. Therapy with leflunomide should be administered cautiously in patients with renal insufficiency.

References

  1. "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Major

Leflunomide (Includes Arava) ↔ tuberculosis

Severe Potential Hazard, Moderate plausibility. Applies to: Tuberculosis -- Active, Tuberculosis -- Latent

Patients should be evaluated for active and latent tuberculosis (TB) infection prior to leflunomide treatment. Leflunomide has not been studied in patients with a positive tuberculosis screen, and the safety of leflunomide in individuals with latent tuberculosis infection is unknown. Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with leflunomide and monitored carefully during leflunomide treatment for possible reactivation of the infection.

Moderate

Leflunomide (Includes Arava) ↔ hypertension

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypertension

Hypertension was reported as an adverse reaction in patients on leflunomide. Blood pressure should be monitored during treatment and periodically thereafter as this agent can increase the blood pressure in these patients.

Arava (leflunomide) drug interactions

There are 772 drug interactions with Arava (leflunomide)

Arava (leflunomide) alcohol/food interactions

There are 2 alcohol/food interactions with Arava (leflunomide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide